首页 / 产品 / 蛋白 / 细胞因子、趋化因子与生长因子
| 纯度 | >95%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CXCL1 |
| Uniprot No | P09341 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 35-107aa |
| 氨基酸序列 | ASVATELRCQCLQTLQGIHPKNIQSVNVKSPGPHCAQTEVIATLKNGRKA CLNPASPIVKKIIEKMLNSDKSN |
| 预测分子量 | kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CXCL1重组蛋白的3篇模拟参考文献示例(非真实文献，供参考格式)：
---
1. **文献名称**: *CXCL1重组蛋白在炎症反应中的功能及信号通路研究*
**作者**: Smith A, et al.
**摘要**: 本研究通过大肠杆菌表达系统制备重组CXCL1蛋白，验证其趋化中性粒细胞的能力，并揭示其通过激活ERK和NF-κB通路促进炎症反应的机制。
---
2. **文献名称**: *重组CXCL1通过调控肿瘤微环境促进乳腺癌转移*
**作者**: Chen L, et al.
**摘要**: 利用哺乳动物细胞表达的重组CXCL1蛋白，发现其通过结合CXCR2受体增强肿瘤相关巨噬细胞浸润，进而促进乳腺癌细胞侵袭和血管生成。
---
3. **文献名称**: *基于结构优化的CXCL1重组蛋白抗病毒活性研究*
**作者**: Wang Y, et al.
**摘要**: 通过点突变技术改造CXCL1结构，获得高稳定性的重组蛋白，证实其可通过竞争性抑制病毒颗粒与宿主细胞结合，降低疱疹病毒感染效率。
---
(注：以上内容为示例，实际文献需通过PubMed/Google Scholar等平台检索。)
CXCL1 (C-X-C motif chemokine ligand 1), also known as growth-regulated oncogene-alpha (GROα), is a small secreted protein belonging to the CXC chemokine family. It functions as a potent chemoattractant for neutrophils by binding to its cognate receptor CXCR2. playing critical roles in inflammatory responses, angiogenesis, and tumor progression. Structurally, CXCL1 consists of approximately 73 amino acids with conserved cysteine residues forming disulfide bonds that stabilize its three-dimensional structure. Its expression is induced by pro-inflammatory cytokines (e.g., IL-1β, TNF-α) and microbial components, regulating immune cell recruitment to sites of infection or tissue injury.
Recombinant CXCL1 protein is engineered using expression systems such as *E. coli* or mammalian cells, followed by purification via chromatography techniques to ensure high purity and bioactivity. The recombinant form retains native functionality, enabling researchers to study CXCL1-mediated signaling pathways, neutrophil migration assays, and its involvement in disease models. In cancer biology, CXCL1 overexpression correlates with tumor growth, metastasis, and immunosuppression, making it a potential therapeutic target. Additionally, recombinant CXCL1 serves as a critical tool for drug screening, antibody development, and mechanistic studies in autoimmune disorders, chronic inflammation, and wound healing.
The availability of recombinant CXCL1 has advanced translational research by overcoming limitations of isolating natural protein from biological fluids, ensuring batch-to-batch consistency, and enabling structure-function studies. Current applications extend to in vitro and in vivo models to explore its dual role in host defense and pathological conditions. Ongoing research focuses on modulating CXCL1-CXCR2 interactions to develop inhibitors for inflammatory diseases and cancer immunotherapy, highlighting its significance in both basic science and clinical investigation. As a biomarker, CXCL1 levels in serum or tissues are increasingly studied for diagnostic or prognostic value in various malignancies and inflammatory syndromes.
×
